Thalidomide prolongs disease stabilization after conventional therapy in patients with recurrent glioblastoma

Oncology Reports

Volumn 11, Issue 1, 2004, Pages 93-95

  Morabito, Alessandro ^a   Fanelli, Massimo ^a   Carillio, Guido ^a   Gattuso, Domenico ^a   Sarmiento, Roberta ^a   Gasparini, Giampietro ^a  

^a SAN FILIPPO NERI HOSPITAL   (Italy)

Author keywords

Recurrent glioblastoma; Thalidomide; Therapeutic options

Indexed keywords

ANGIOGENESIS INHIBITOR; THALIDOMIDE;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; CONSTIPATION; DISEASE COURSE; FEMALE; GLIOBLASTOMA; HEADACHE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; SLEEP DISORDER; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; CONSTIPATION; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HEADACHE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SLEEP DISORDERS; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 3543132551     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.11.1.93     Document Type: Article

References (27)

1. Weber D, Rankin K, Gavino M, Delasalle K and Alexanian R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 21: 16-19, 2003.
2. Gasparini G, Morabito A, Magnani E, Gattuso D, Capaccetti B and Alberti AM: Thalidomide: an old sedative-hypnotic with anticancer activity? Curr Opin Invest Drugs 2: 1302-1308, 2001. (Pubitemid 32878612)
3. Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A, Roccaro AM and Gasparini G: Thalidomide: a new anticancer drug? Expert Opin Investig Drugs 12: 1211-1225, 2003. (Pubitemid 36857209)
4. D'Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085, 1994. (Pubitemid 24139577)
5. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K and Dannemberg AJ: Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res 7: 3349-3355, 2001. (Pubitemid 33069965)
6. Moreira AL, Tsenova-Berkova L, Wang J, Laochumroonvorapong P, Freedman VH and Kaplan G: Effect of cytokine modulation by thalidomide on the granulomatous response in murine tuberculosis. Tubercle Lung Dis 78: 47-55, 1997. (Pubitemid 28019787)
7. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Flockhart DA, Trinchieri G and Karp CL: Inhibition of IL-12 production by thalidomide. J Immunol 159: 5157-5161, 1997. (Pubitemid 127471057)
8. Shannon EJ and Sandoval F: Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 31: 109-116, 1995.
9. Partida-Sanchez S, Favila-Castillo L, Pedraza-Sanchez S, Gomez-Melgar M, Saul A, Estrada-Parra S and Estrada-Garcia I: IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment. Int Arch Allergy Immunol 116: 60-66, 1998. (Pubitemid 28211959)
10. Haslett PA, Corral LG, Albert M and Kaplan G: Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. J Exp Med 187: 1885-1892, 1998. (Pubitemid 28262451)
11. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
12. Brem S, Cotran R and Folkman J: Tumor angiogenesis: a quantitative method for histologic grading. J Natl Cancer Inst 48: 347-356, 1972.
13. Plate KH, Breier G, Weich HA, et al: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.
14. Takahashi JA, Fukumoto M, Igarashi K, Oda Y, Kikuchi H and Hatamaka M: Correlations of basic fibroblast growth factor expression levels with degree of malignancy and vascularity in human gliomas. J Neurosurg 76: 792-798, 1992.
15. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J II, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB and Strike TA: Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329, 1980. (Pubitemid 11194457)
16. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S and Levin VA: A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593, 2000. (Pubitemid 30636298)
17. Dinnes J, Cave C, Huang S and Milne R: A rapid and systemic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 86: 501-505, 2002. (Pubitemid 34185082)
18. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL and Miller LL: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516-1525, 1999. (Pubitemid 29220860)
19. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, Gilbert M, Newton HB and Hellman R: Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 8: 1485-1491, 2003. (Pubitemid 46594100)
20. Robins HI, Chang S, Prados MD, Yung WK, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn IG, Cloughesy T, Junck L and Mehta M: A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neurooncology 4: 109-114, 2002. (Pubitemid 34285065)
21. Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J and Piantadosi S: Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. J Clin Oncol 15: 3121-3128, 1997. (Pubitemid 27377504)
22. Huncharek M, Muscat J and Geschwind JF: Multi-drug versus single agent chemotherapy for high grade astrocytoma: result of a meta-analysis. Anticancer Res 18: 4693-4697, 1998. (Pubitemid 29042045)
23. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J and Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571, 1999.
24. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM and Yung WKA: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 18: 708-715, 2000. (Pubitemid 30106600)
25. Short SC, Traish D, Dowe A, Hines F, Gore M and Brada M: Thalidomide as an anti-angiogenic agent in relapsed gliomas. J Neurooncol 51: 41-45, 2001. (Pubitemid 32321900)
26. Marx GM, Pavlakis N, McCowatt S, Boyle FM, Levi JA, Bell DR, Cook R, Biggs M, Little N and Wheeler HR: Phase II study of thalidomide in the treatment of recurrent glioblastoma multiforme. J Neurooncol 54: 31-38, 2001. (Pubitemid 33089257)
27. Hwu WJ, Krown SE, Panageas KS, Menell JH, Chapman PB, Livingston PO, Williams LJ, Quinn CJ and Houghton AN: Temozolamide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J Clin Oncol 20: 2610-2615, 2002. (Pubitemid 34575632)